Trial Profile

A Phase 1, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety and Pharmacokinetics of HB0025 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HB 0025 (Primary)
Indications Endometrial cancer; Liver cancer; Non-small cell lung cancer; Renal cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Huabo Biopharm

Most Recent Events

04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2023 Results (n=30, Data cut off date- 30 july 2022), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
24 Apr 2022 Planned number of patients changed from 54 to 154.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com